EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSBSLG00000014488
Gene Symbol: CACNG8
3 Cross references
163 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSBSLG00000002008
Gene Symbol: CACNA1A
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSBSLG00000005686
Gene Symbol: CACNA1A
3 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSBSLG00000003429
Gene Symbol: CACNA1D
3 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSBSLG00000017267
Gene Symbol: CACNA1E
3 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSBSLG00000001891
Gene Symbol: CACNA1E
3 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSBSLG00000024518
Gene Symbol: CACNA1G
3 Cross references
197 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSBSLG00000019682
Gene Symbol: CACNA1H
3 Cross references
210 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSBSLG00000026525
Gene Symbol: CNR1
3 Cross references
135 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSBSLG00000008106
Gene Symbol: CNR1
1 Cross references
154 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSBSLG00000021011
Gene Symbol: LOC114842776
3 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSBSLG00000012772
Gene Symbol: CA12
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).